Tumor profiling using protein biomarker panels in malignant melanoma: Application of tissue microarrays and beyond

Expert Review of Proteomics

Volumn 9, Issue 4, 2012, Pages 415-423

  Joyce, Cormac W ^a,b   Murphy, Ian G ^a,b   Rafferty, Mairin ^a,c   Ryan, Denise ^a   McDermott, Enda W ^b   Gallagher, William M ^a,c  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^c ONCOMARK LIMITED   (Ireland)

Author keywords

biomarkers; clinical implementation; immunohistochemistry; melanoma; tissue microarrays

Indexed keywords

B RAF KINASE; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HLA ANTIGEN CLASS 1; IPILIMUMAB; PROTEIN BCL 6; PROTEIN P53; STEM CELL FACTOR RECEPTOR; TUMOR MARKER;

CYTOPLASM; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MELANOMA; ONCOGENE N RAS; PROTEIN EXPRESSION; PUNCH BIOPSY; REVIEW; SKIN BIOPSY; TISSUE MICROARRAY;

CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; GENETIC TESTING; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84866328917     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/epr.12.5     Document Type: Review

References (59)

1. Tsao H, Atkins MB, Sober AJ. Managementof cutaneous melanoma. N. Engl. J. Med. 351(10), 998-1012 (2004).
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. CA Cancer J. Clin. 55(2), 74-108 (2005).
3. De Vries TJ, Fourkour A, Wobbes T, Verkroost G, Ruiter DJ, van Muijen GN. Heterogenous expression of immunotherapy candidate proteins gp100, MART1, and tyrosine in human melanoma cell lines and in human melanocytic lesions. Cancer Res. 57(15), 3223-3229 (1997). (Pubitemid 27351739)
4. Dennis LK, Vanbeek MJ, Beane Freeman LE, Smith BJ, Dawson DV, Coughlin JA. Sunburns and risk of cutaneous melanoma: Does age matter? A comprehensive meta-analysis. Ann. Epidemiol. 18(8), 614-627 (2008). (Pubitemid 352001390)
5. Herlyn M. Human melanoma: Development and progression. Cancer Metastasis Rev. 9(2), 101-112 (1990). (Pubitemid 20311827)
6. Mohammed KS, Javelaud D, Fournier PG et al. TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases. Cancer Res. 71(1), 175-184 (2011).
7. Aktaş A, Hoş G, Topaloǧlu, Calik A, Reis A, Pişkin B. Metastatic cutaneous melanoma presented with ileal invagination: Report of a case. Ulus Travma Acil Cerrahi Derg. 16(5), 469-472 (2010).
8. Chin L, Merlino G, DePinho RA. Malignant melanoma: Modern black plague and genetic black box. Genes Dev. 12(22), 3467-3481 (1998). (Pubitemid 28553239)
9. Balch CM, Gershenwald JE, Soong SJ et al. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 27(36), 6199-6206 (2009).
10. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol. 14(1), 7-17 (1996).
11. Kirkwood JM, Ibrahim JG, Sondak VK et al. High and low-dose interferon alfa-2b in high risk melanoma: First analysis of intergroup trial E1690/S9111/C9190. J. Clin. Oncol. 18(12), 2444-2458 (2000). (Pubitemid 30415832)
12. Kirkwood JM, Ibrahim JG, Sosman JA et al. High dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/S9512/C509801. J. Clin. Oncol. 19(9), 2370-2380 (2001). (Pubitemid 32391207)
13. Gray Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature 445(7130), 851-857 (2007).
14. Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363(9), 809-819 (2010).
15. Gimotty PA, Guerry D. Prognostication in thin cutaneous melanomas. Arch. Pathol. Lab. Med. 134(12), 1758-1763 (2010).
16. Gaynor R, Irie R, Morton D, Herschman HR. S100 protein is present in cultured human malignant melanomas. Nature 286(5771), 400-401 (1980). (Pubitemid 10002887)
17. Gaynor R, Herschman HR, Irie R, Jones P, Morton D, Cochran A. S100 protein: A marker for human malignant melanomas? Lancet 1(8225), 869-871 (1981). (Pubitemid 11099318)
18. Xerri L, Grob JJ, Battayani Z, Gouvernet J, Hassoun J, Bonerandi JJ. NM23 expression in metastasis of malignant melanoma is a predictive prognostic parameter correlated with survival. Br. J. Cancer 70(6), 1224-1228 (1994). (Pubitemid 24358967)
19. Pacifico MD, Grover R, Richman PI, Buffa F, Daley FM, Wilson GD. Nm23 as a prognostic marker in primary cutaneous melanoma: Evaluation using tissue microarray in a patient group with long term follow up. Melanoma Res. 15(5), 435-440 (2005). (Pubitemid 41558954)
20. Talantov DA, Mazumder JX, Yu T et al. Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin. Cancer Res. 11(20), 7234-7242 (2005).
21. Bittner M, Meltzer P, Chen Y et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406(6795), 536-540 (2000). (Pubitemid 30625740)
22. Haqq CM, Nosrati M, Sudilsovsky D et al. The gene expression signatures of melanoma progression. Proc. Natl Acad. Sci. USA 102(17), 6092-6097 (2005). (Pubitemid 40594260)
23. Winnepenninckx V, Lazar V, Michiels S et al. Gene expression profiling of primary cutaneous melanoma and clinical outcome. J. Natl Cancer Inst. 98(7), 472-482 (2006).
24. Gast A, Scherer D, Chen B et al. Somatic alterations in the melanoma genome: A high resolution array-based comparative hybridization study. Genes Chromosomes Cancer 49(8), 733-745 (2010).
25. Kononen J, Bubendorf L, Kallioniemi A et al. Tissue microarrays for high throughput molecular profiling of tumour specimens. Nat. Med. 4(7), 844-847 (1998). (Pubitemid 28331029)
26. Battifora H. The multitumor (sausage) tissue block: Novel method for immunohistochemical antibody testing. Lab. Invest. (2), 244-248 (1986). (Pubitemid 16017550)
27. Chung JY, Braunschweig T, Baibakov G et al. Transfer and multiplex blotting of a paraffin embedded tissue. Proteomics 6(3), 767-774 (2004). (Pubitemid 43260202)
28. Parsons P, Grabsch H. How to make tissue microarrays. Diagn. Histopathol. 15(3), 142-150 (2009).
29. Kluger HM, Di Vito K, Berger AJ et al. Her2.neu is not a commonly expresses therapeutic target in melanoma - a large cohort tissue microarray study. Melanoma Res. 14(3) 207-210 (2004). (Pubitemid 38879583)
30. Berger AJ, Davis DW, Tellez C et al. Automated quantitative analysis of activator protein 2-alpha subcellular expression in melanoma tissue microarrays correlates with survival prediction. Cancer Res. 65(23), 11185-11192 (2005). (Pubitemid 41713390)
31. Scolyer RA, Shaw HM, Thompson JF et al. Interobserver reproducibility of histopathologic prognostic variables in primary cutaneous melanomas. Am. J. Surg. Pathol. 27(12), 1571-1576 (2003). (Pubitemid 37486620)
32. Arihiro K, Umemura S, Kurosumi M et al. Comparison of evaluations for hormone receptors in breast carcinoma using two manual and three automated immunohistochemical assays. Am. J. Clin. Pathol. 127(3), 356-365 (2007). (Pubitemid 46806328)
33. Fine JL, Grzybicki DM, Silowash R et al. Evaluation of whole slide immunohistochemistry interpretation in challenging prostate needle biopsies. Hum. Pathol. 39(4), 564-572 (2008).
34. Mulrane L, Rexhepaj E, Penney S et al. Automated image analysis in histopathology: A valuable tool in medical diagnostics. Expert Rev. Mol. Diagn. 8(6), 707-725 (2008).
35. Uhlen M, Björling E, Agaton C et al. A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol. Cell Proteomics 4(12), 1920-1932 (2005). (Pubitemid 41830186)
36. Brennan DJ, O'Connor DP, Rexhepaj E et al. Antibody-based proteomics: Fasttracking molecular diagnostics in oncology. Nat. Rev. Cancer 10(9), 605-617 (2010).
37. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat. Med. 8(11), 1323-1327 (2002). (Pubitemid 35373567)
38. Shields JM, Thomas NE, Cregger M et al. Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signalling shows a new type of melanoma. Cancer Res. 67(4), 1502-1512 (2007). (Pubitemid 46389241)
39. McCarthy MM, Di Vito KA, Sznol M et al. Expression of tumour necrosis factor-related apoptosis-inducing ligand receptors 1 and 2 in melanoma. Clin. Cancer Res. 12(2), 3856-3863 (2006). (Pubitemid 44000268)
40. Gremel G, Rafferty M, Lau TY, Gallagher TM. Identification and functional validation of therapeutic targets for malignant melanoma. Crit. Rev. Oncol. Hematol. 72(3), 194-214 (2009).
41. Nielsen TO, Hsu FD, Jensen K et al. Immunohistochemical and clinical characterisation of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. 10(16), 5367-5374 (2004). (Pubitemid 39100473)
42. Cooper S. First Lines of Theory and Practice of Surgery. Longman, Orme, Brown, Green and Longman, London, UK (1840).
43. McMasters KM. The Sunbelt Melanoma Trial. Ann. Surg. Oncol. 8(9 Suppl.), S41-S43 (2001).
44. Kirkwood JM, Ibrahim JG. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin. Cancer Res. 10(5), 1670-1677 (2004). (Pubitemid 38435557)
45. Lui P, Cashin R, Machado, Hemels M, Corey-Lisle PK, Einarson TR. Treatments for metastatic melanoma: Synthesis of evidence from randomized trials. Cancer Treat. Rev. 33(8), 665-680 (2007). (Pubitemid 350082665)
46. Sarnaik AA, Yu B, Yu D et al. Extended dose ipilimumab with a peptide vaccine: Immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. Clin. Cancer Res. 17(4), 896-906 (2011).
47. Weber J, Thompson JA, Hamid O et al. A randomized, double-blind, placebocontrolled, Phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin. Cancer Res. 15(17), 5591-5598 (2009).
48. Hodi FS, O' Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010).
49. Nazarian RM, Prieto VG, Elder DE, Duncan LM. Melanoma biomarker expression in melanocytic tumor progression: A tissue microarray study. J. Cutan. Pathol. 37(Suppl. 1), 41-47 (2010).
50. Becker D, Mihm MC, Hewitt SM, Sondak VK, Fountain JW, Thurin M. Markers and tissue resources for melanoma: Meeting report. Cancer Res. 66(22), 10652-10657 (2006). (Pubitemid 44876958)
51. Levy C, Khaled M, Fisher DE. MITF: Master regulator of melanocyte development and melanoma oncogene. Trends Mol. Med. 12(9), 406-414 (2006). (Pubitemid 44291572)
52. Thies A, Moll I, Berger J et al. CEACAM expression in cutaneous malignant melanoma predicts the development of metastatic disease. J. Clin. Oncol. 20(10), 2530-2536 (2002). (Pubitemid 34525740)
53. Alonso SR, Tracey L, Ortiz P et al. A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis. Cancer Res. 67(7), 3450-3460 (2007). (Pubitemid 46724886)
54. Kashani-Sabet M, Venna S, Nosradi M et al. A multi-marker prognostic assay for primary cutaneous melanoma. Clin. Cancer Res. 15(22), 6987-6992 (2009).
55. Gould Rothberg BE, Bracken MB, Rimm DL. Tissue biomarkers for prognosis in cutaneous melanoma: A systematic review and meta-analysis. J. Natl Cancer Inst. 101(7), 452-474 (2009).
56. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting mechanisms for tumor marker studies (REMARK). J. Natl Cancer Inst. 97(16), 1180-1184 (2005). (Pubitemid 41258223)
57. Hofbauer GF, Burkhart A, Schuler G, Dummer R, Burg G, Nestle FO. High frequency of melanoma associated antigen or HLA class I loss does not correlate with survival in primary melanoma. J. Immunother. 27(1), 73-78 (2004). (Pubitemid 38076170)
58. Bugonovic D, O'Neill DW, Belitskaya-Levy I. Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc. Natl Acad. Sci. USA 106(48), 20429-20434 (2009).
59. Alonso SR, Ortiz P, Pollan M et al. Progression in cutaneous malignant melanoma is associated with distinct expression profiles; a tissue microarray-based study. Am. J. Pathol. 164(1), 193-203 (2004). (Pubitemid 38364604)